Monopar Therapeutics (MNPR) Return on Capital Employed (2018 - 2020)

Monopar Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 0.37% for Q3 2020.

  • For Q3 2020, Return on Capital Employed rose 46.0% year-over-year to 0.37%; the TTM value through Sep 2020 reached 0.37%, up 46.0%, while the annual FY2019 figure was 0.45%, 4.0% down from the prior year.
  • Return on Capital Employed for Q3 2020 was 0.37% at Monopar Therapeutics, up from 0.37% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.32% in Q1 2020 and bottomed at 2.03% in Q2 2018.
  • The 3-year median for Return on Capital Employed is 0.51% (2019), against an average of 0.77%.
  • The largest YoY upside for Return on Capital Employed was 128bps in 2019 against a maximum downside of -43bps in 2019.
  • A 3-year view of Return on Capital Employed shows it stood at 0.46% in 2018, then dropped by -10bps to 0.51% in 2019, then grew by 28bps to 0.37% in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Return on Capital Employed are 0.37% (Q3 2020), 0.37% (Q2 2020), and 0.32% (Q1 2020).